Purchase this article with an account.
Patricia Odashiro, Alexandre Odashiro, Ana Beatriz Toledo Dias, Pablo Zoroquiain, Denise Miyamoto, Miguel N Burnier; Eyelid Sebaceous Carcinoma and Program cell death ligand 1 expression. Invest. Ophthalmol. Vis. Sci. 2017;58(8):3363.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Sebaceous Carcinoma (SC) is a very aggressive malignant tumor and represents the 2nd or 3rd most common malignant tumor of the eyelid. The expression of Programmed Death-1 ligand (PD-L1) by tumor cells is an effective mechanism to escape anti-tumor immunity. PD-1/PD-L1 blockade by monoclonal antibodies are emerging as an effective treatment option in multiple malignant tumors. There are currently no studies in the literature investigating the PD-L1 expression in SC.
Eighteen cases of formalin-fixed, paraffin-embedded eyelid SC were evaluated for PD-L1 expression by immunohistochemistry using the Ventana system. The slides were digitalized and the Aperio software for imaging analyzes was used. The percentage and intensity of the membranous cells staining was record.
Nine (50%) out of 18 cases showed expression of PD-L1 ranging from 1% to 15% of the SC cells. In 2 (11%) of the positive cases, there were cells with strong or moderate complete membranous pattern of staining. The other 7 (39%) positive cases showed weak or incomplete membranous pattern of staining
Our data show that a half of the SC express PD-L1. This supports the relevance of more studies and clinical trials to test the efficacy of PD-1 inhibitors for the treatment of SC.
This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.
This PDF is available to Subscribers Only